Cover Image
Market Research Report

Naturlose (Type 2 Diabetes) - Analysis and Forecasts to 2020

Published by GlobalData Product code 232345
Published Content info 40 Pages
Immediate Delivery Available
Price
Back to Top
Naturlose (Type 2 Diabetes) - Analysis and Forecasts to 2020
Published: January 31, 2012 Content info: 40 Pages
Description

Summary

GlobalData's pharmaceuticals report, "Naturlose (Type 2 Diabetes) - Analysis and Forecasts to 2020" provides Naturlose sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2012-2020). The report also includes information on Type 2 Diabetes market. This report is built using data and information sourced from GlobalData's proprietary databases, primary and secondary research using Company's corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope

  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Naturlose
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Naturlose including efficacy, safety, pricing and other details which influence its sales potential
  • Detailed sales forecast for 2012-2020 for Naturlose in each of the seven major markets

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drug's performance
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
Table of Contents

Table of contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1 Diabetes Market
  • 2.2. Epidemiology
    • 2.2.1. Prevalence
    • 2.2.2. Mortality
  • 2.3. Etiology and Risk Factors
    • 2.3.1. Obesity
    • 2.3.2. Sedentary Lifestyle
    • 2.3.3. Family History and Genetics
    • 2.3.4. Ethinicity
    • 2.3.5. Old Age
  • 2.4. Economic Impact of Diabetes
  • 2.5. GlobalData Report Guidance

3. Type 2 Diabetes: Market Characterization

  • 3.1. Type 2 Diabetes Market
  • 3.2. Type 2 Diabetes Market Forecasts and CAGR
  • 3.3. Type 2 Diabetes Market: Drivers and Restraints
    • 3.3.1. Drivers
    • 3.3.2. Restraints

4. Classification of Diabetes

  • 4.1. Types of Diabetes
    • 4.1.1. Type1 Diabetes
    • 4.1.2. Type 2 Diabetes
    • 4.1.3. Gestational Diabetes
  • 4.2 Diabetes Complications
    • 4.2.1. Cardiovascular Disease
    • 4.2.2. Nephropathy
    • 4.2.3. Neuropathy
    • 4.2.4. Amputation
    • 4.2.5. Retinopathy

5. Evolution of Anti-Diabetic Treatments

6. Medications

  • 6.1. Insulin
  • 6.2. Oral Medications
    • 6.2.1. Sulfonylureas (SUR)
    • 6.2.2. Biguanides (BGDs)
    • 6.2.3. Alpha-Glucosidase Inhibitors (AGI)
    • 6.2.4. Meglitinides
    • 6.2.5. Thiazolidinediones (TZDs)
    • 6.2.6. Dipeptidyl Peptidase IV (DPP-4) Inhibitors
    • 6.2.7. Oral Combination Therapy
  • 6.3. Other Injectionable Medications
    • 6.3.1. Pramlintide
    • 6.3.2. Exenatide
  • 6.4. Market Share as per Classes in Type 2 Diabetes

7. Naturlose

  • 7.1. Introduction
  • 7.2. Mechanism of Action
  • 7.3. Clinical Studies
  • 7.4. Factors Affecting Sales of Naturlose
    • 7.4.1. Almost No Calories
    • 7.4.2. High Safety Profile
  • 7.5. Drug Evaluation
    • 7.5.1. Drug Risk Benefit Score
    • 7.5.2. Intensity of Competition
  • 7.6. Sales Forecasts
    • 7.6.1. Target Patient Pool
    • 7.6.2. Dosing
    • 7.6.3. Market Penetration
    • 7.6.4. Annual Cost of Therapy
    • 7.6.5. Sales Projections of Naturlose

8 Diabetes Market: Appendix

  • 8.1. Market Definitions
  • 8.2. List of Abberiviations
  • 8.3. Research Methodology
    • 8.3.1. Coverage
    • 8.3.2. Secondary Research
    • 8.3.3. Forecasting
    • 8.3.4. Number of patients approved to take the drug
    • 8.3.5. Net Penetration of Drug
    • 8.3.6. Net Annual Dosing
    • 8.3.7. Annual Cost of Therapy
  • 8.4. Drug Sales Estimates Model
  • 8.5. Contact Us
  • 8.6. Disclaimer
  • 8.7. Sources

List of Tables

  • Table 1: Diabetes, World, Prevalence Estimates for the age group 20-79 years (million), 2000-2030
  • Table 2: Diabetes, Top 10 Countries, by Prevalence (million), 2010 and 2030
  • Table 3: Diabetes, Top 10 Countries, Highest Health Expenditures ($bn), 2010
  • Table 4: Type 2 Diabetes, World, Major Marketed Drugs, 2010
  • Table 5: Type 2 Diabetes, World, Major Pipeline Products in Phase III
  • Table 6: Diabetes, Worldwide, Prevalence Estimates, 2010 and 2030
  • Table 7: Overweight*, Global, Prevalence Estimates in Males Aged 15 and above (%), 2005
  • Table 8: Diabetes Drugs Evolution
  • Table 9: Phase II Trial Results
  • Table 10: Drug Risk Benefit Score of Naturlose
  • Table 11: Naturlose, Type 2 Diabetes, Global, Sales Estimates ($m), 2012-2020
  • Table 12: Naturlose, Type 2 Diabetes, The US, Sales Estimates ($m), 2012-2020
  • Table 13: Naturlose, Type 2 Diabetes, UK, Sales Estimates ($m), 2012-2020
  • Table 14: Naturlose, Type 2 Diabetes, France, Sales Estimates ($m), 2012-2020
  • Table 15: Naturlose, Type 2 Diabetes, Germany, Sales Estimates ($m), 2012-2020
  • Table 16: Naturlose, Type 2 Diabetes, Italy, Sales Estimates ($m), 2012-2020
  • Table 17: Naturlose, Type 2 Diabetes, Spain, Sales Estimates ($m), 2012-2020
  • Table 18: Naturlose, Type 2 Diabetes, Japan, Sales Estimates ($m), 2012-2020

List of Figures

  • Figure 1: Diabetes, World, Comparative Prevalence in Age Group 20-79 years (in %), 2010
  • Figure 2: Diabetes, World, Comparative Prevalence in Age Group 20-79 years (in %), 2030
  • Figure 3: Diabetes, World, Mortality, 2010
  • Figure 4: Top 10 Causes of Mortality, Worldwide, 2008
  • Figure 5: Type 2 Diabetes, Global, Market Size Forecasts ($bn), 2010-2020
  • Figure 6: Mechanism of Action of Sulfonylurea
  • Figure 7: Mechanism of Action of Biguanide, Thiazolidinediones, Alpha-Glucosidase Inhibitors
  • Figure 8: Mechanism of Action of Metformin and Alpha-Glucosidase Inhibitors
  • Figure 9: Mechanism of Action of Thiazolidinediones
  • Figure 10: Mechanism of Action of DPP-IV Inhibitors
  • Figure 11: Type 2 Diabetes, Global, Market Share as per Classes (%), 2010
  • Figure 12: Naturlose, Type 2 Diabetes , Global, Sales Estimates ($m), 2012-2020
  • Figure 13: Naturlose, Type 2 Diabetes, The US, Sales Estimates ($m), 2012-2020
  • Figure 14: Naturlose, Type 2 Diabetes, UK Sales Estimates ($m), 2012-2020
  • Figure 15: Naturlose, Type 2 Diabetes, France, Sales Estimates ($m), 2012-2020
  • Figure 16: Naturlose, Type 2 Diabetes, Germany, Sales Estimates ($m), 2012-2020
  • Figure 17: Naturlose, Type 2 Diabetes, Italy, Sales Estimates ($m), 2012-2020
  • Figure 18: Naturlose, Type 2 Diabetes, Spain, Sales Estimates ($m), 2012-2020
  • Figure 19: Naturlose, Type 2 Diabetes, Japan, Sales Estimates ($m), 2012-2020
  • Figure 20: Naturlose, Type 2 Diabetes, Sales Distribution by Country (%), 2020
  • Figure 21: Patients Approved for the Drug
Back to Top